BMY - Bristol-Myers Squibb Company
| Previous Close | 58.98 |
| Open | 59.30 |
| Bid | 58.91 x 1200 |
| Ask | 59.30 x 1000 |
| Day's Range | 58.76 - 59.64 |
| 52 Week Range | 42.48 - 68.34 |
| Volume | 11,366,050 |
| Avg. Volume | 16,214,029 |
| Market Cap | 133.815B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | 115.28 |
| EPS (TTM) | 0.51 |
| Earnings Date | Aug. 06, 2020 |
| Forward Dividend & Yield | 1.80 (3.04%) |
| Ex-Dividend Date | Jul. 02, 2020 |
| 1y Target Est | 71.36 |
- Zacks
Is Bristol Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "
Bristol Myers (BMY) could produce exceptional returns because of its solid growth attributes.
- Reuters
FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show. The Food and Drug Administration (FDA) has approved more than 30 new medicines since January, but at least five drugmakers including Bristol Myers Squibb, Sanofi , Neurocrine Biosciences, Endo Pharmaceuticals and Aimmune have changed their launch plans.
- Reuters
Canada federal court dismisses drugmakers' plea challenging drug price rules
The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade. The court struck down one part of the new regulation, finding that using certain payments to third parties to determine a drug's regulated price went beyond the government's authority, but upheld the bulk of the rules. Canada published the final regulations in August last year, despite strong opposition from drug companies.
- Zacks
Bristol Myers & Acceleron Obtain EC Approval for Reblozyl
Bristol Myers (BMY) and partner Acceleron win EC approval of Reblozyl (luspatercept) for two indications.
- Business Wire
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndrome
- Zacks
Bristol Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy? (Revised)
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol Myers Squibb (BMY) have what it takes? Let's find out.
- Zacks
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina
- Zacks
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb
- Zacks
Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
- Zacks
Top Research Reports for Netflix, Bristol-Myers & NextEra
Top Research Reports for Netflix, Bristol-Myers & NextEra
- Business Wire
Bristol Myers Squibb to Announce Results for Second Quarter 2020 on August 6, 2020
Bristol Myers Squibb to Announce Results for Second Quarter 2020 on August 6, 2020
- Thomson Reuters StreetEvents
Edited Transcript of BMY earnings conference call or presentation 7-May-20 12:30pm GMT
Q1 2020 Bristol-Myers Squibb Co Earnings Call
- Zacks
Bristol-Myers Squibb (BMY) Stock Moves -0.19%: What You Should Know
Bristol-Myers Squibb (BMY) closed at $56.95 in the latest trading session, marking a -0.19% move from the prior day.
- Business Wire
Bristol Myers Squibb Announces Commencement of Registered Exchange Offers
Bristol Myers Squibb Announces Commencement of Registered Exchange Offers
- Zacks
3 Reasons Growth Investors Will Love Bristol-Myers (BMY)
Bristol-Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- Motley Fool
Have $500? Here Are the Best Stocks to Buy During a Correction
Panic and uncertainty tied to the coronavirus disease 2019 (COVID-19) pandemic initially pushed the broad-based S&P 500 into bear market territory in just 17 trading sessions. As recently as last week, the S&P 500 had bounced more than 40% from its lows and appeared to have established a new bull market. Historically speaking, a correction or crash following a major bounce from a bear market bottom is perfectly normal and expected.
- Zacks
Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Business Wire
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
FDA Approves Opdivo for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) ....
- Zacks
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
Bristol-Myers Squibb (BMY) closed at $60.16 in the latest trading session, marking a -1.26% move from the prior day.
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT
NEW YORK, June 08, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY.RT)..
- Motley Fool
3 Top Biotech Stocks to Buy in June
Investors seeking to beat the market should take a long and hard look at biotech stocks. Here are three top biotech stocks that I think are great picks to buy in June. There's too much to like about Vertex Pharmaceuticals (NASDAQ: VRTX) for it not to top the list.
- Zacks
Bristol-Myers (BMY) Up 0.5% Since Last Earnings Report: Can It Continue?
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
